Micronuclei, dmin chromosomes and MYC amplifications as a singular presentation of myeloid malignancies

et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944– 50. 6. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136–52. 7. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, et al. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(7):1059–64. 8. Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, et al. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019;33(2):98–110. 9. Orlowski RJ, Porter DL, Frey NV. The promise of chimeric antigen receptor T cells (CARTs) in leukaemia. Br J Haematol. 2017;177(1):13– 26. 10. Grant, KUnceratin, costly, but filled with hope: gene therapy about to go mainstream in Canada. THE GLOBE AND MAIL. 2018 [cited 2019 Sep 20]. Available from: https://www.theglobeandmail. com/canada/article-unce rtain-costly-but-filled-with-hope-gene-therapy-about-to-go/ 11. Tisagenlecleucel for acute lymphoblastic leukemia and diffuse large b-cell lymphoma: Recommendations. Ottawa: CADTH; 2019 Jan. (CADTH optimal use report, vol. 8, no. 3g). 12. Davies C, Briggs A, Lorgelly P, Garellick G, Malchau H. The, “hazards” of extrapolating survival curves. Med Decis Making. 2013;33(3):369–80. 13. Zlomislic D. Top doctors, health critics blast Health Minister Eric Hoskins for stem cell transplant crisis. THE STAR. 2016 [cited 2019 Sep 20]. https://www.thestar. com/news/canada/2016/04/20/top-docs-health-critic-bla st-hoskins-for-stem-cell-crisis.html 14. Supply and demand: why patients have to wait for stem cell transplants. CTV NEWS. 2015. Published Wednesday, July 15, 2015 [cited 2019 Sep 20]. https://www.ctvnews. ca/health/supply-and-demand-why-patients-haveto-wait-for-stem-cell-transplants-1.2470014 15. Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156–64. 16. Institute of Medicine Forum on Drug Discovery D, Translation. The National Academies Collection: Reports funded by National Institutes of Health. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington (DC): National Academies Press (US) National Academy of Sciences; 2010. 17. Cheng SK, Dietrich MS, Dilts DM. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials. Clin Cancer Res. 2011;17(7):1947–55. 18. Bonfiglio GA.Proteus Venture Partners Cell therapy clinical trials: why they fail. IBC Inaugural Cell Therapy Clinical Development Conference, Arlington, VA. 2012. 19. Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting Low Accrual in the National Cancer Institute’s Cooperative Group Clinical Trials. J Natl Cancer Inst. 2016;108(2):djv324. 20. Denicoff A, Massett HA, Mishkin GE, Bangs R, Berlin J, Bischoff MB, et al. Creating a national collaborative strategy to enhance trial accrual in NCI’s National Clinical Trials Network (NCTN) in the era of precision medicine. American Society of. Clin Oncol. 2015;33(15_suppl):6589. 21. Horvat TZ, Seddon AN, Ogunniyi A, King AC, Buie LW, Daley RJ. The ABCs of immunotherapy for adult patients with B-cell acute lymphoblastic leukemia. Ann Pharmacother. 2018;52(3):268–76. 22. Topp MS, Gokbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66. 23. Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47. 24. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53.